首页> 外文期刊>Viral immunology >Development of a Time and Cost Benefit Antibody Binding Test-Based Method for Determination of Rabies Vaccine Potency
【24h】

Development of a Time and Cost Benefit Antibody Binding Test-Based Method for Determination of Rabies Vaccine Potency

机译:开发时间和成本效益抗体结合基于测试的狂犬病疫苗效力的方法

获取原文
获取原文并翻译 | 示例
       

摘要

This study is an improvement on the antibody binding test, known as ABT method, to develop a simple and fast method in comparison with NIH for determination of rabies vaccine potency. In the current study, several commercial human and veterinary vaccines were tested using both modified ABT and NIH methods. The ED50 was calculated using the probit method and the relative potency of each vaccine was measured based on the reference vaccine. The test was repeated four times to calculate the reproducibility of the method. Statistical analysis indicated that there was no significant difference between the result obtained from NIH and modified ABT method for either human or veterinary vaccines (p > 0.05). In addition, the linearity of the method (R-2) was calculated as 0.94 by serial dilution of a test vaccine. Coefficient variances were determined as less than and more than 10% for the human and veterinary rabies vaccines, respectively. In conclusion, the findings suggest that the modified method could be considered as an alternative approach for rabies vaccine potency determination in in-process quality control tests at industrial scale. It is a time and cost benefit method and accuracy may further be increased by employing monoclonal antibodies against trimeric form of G glyco-protein. However, the use of serum samples may be useful compared with an artificial mix of antibodies because other components from the serum samples could have a positive impact on cell sensitivity and mimic more the complexity of the immune response. Although the modified test has solved a fundamental problem, it is still not sensitive enough for veterinary vaccine assessment and needs further modifications to obtain the acceptability criteria.
机译:该研究是对称为ABT方法的抗体结合试验的改善,与NIH测定狂犬病疫苗效力的抗体结合试验。在目前的研究中,使用改性的ABT和NIH方法测试了几种商业人和兽医疫苗。使用探测方法计算ED50,并基于参考疫苗测量每种疫苗的相对效力。重复测试4次以计算该方法的再现性。统计分析表明,从NIH和改性ABT方法获得的结果没有显着差异,用于人或兽医疫苗(P> 0.05)。另外,通过串联稀释测试疫苗计算方法(R-2)的线性度为0.94。对于人和兽医狂犬病疫苗,系数差异分别被确定为小于和超过10%的疫苗。总之,研究结果表明,改性方法可被认为是狂犬病疫苗效力测定在工业规模的过程内质量控制试验中的替代方法。通过使用针对三聚甘油蛋白的三聚体形式的单克隆抗体,可以进一步增加时间和成本效益方法和准确性。然而,与抗体的人造混合物相比,使用血清样品的使用可能是有用的,因为来自血清样品的其他组分可能对细胞敏感性产生正影响并模仿免疫应答的复杂性。虽然修改测试已经解决了一个根本的问题,但对于兽医疫苗评估仍然不敏感,并且需要进一步修改以获得可接受性标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号